Discounted New Balance Men’s The 501 Shoes

Metalonmetal acetabular system sales experienced 11.5% growth in Europe during the first quarter with 9% growth in the United States. with the introduction in fiscal year 2006.

The boneconserving ReCap Total Resurfacing System, which is indicated for patients in the early stages of degenerative joint disease continues to experience strong market acceptance in Europe.

Biomet's Taperloc porous coated hip stems continued to repeat excellent market demand worldwide during the first quarter. In Europe, the Aura, Aura II and the Biometric stems also experienced strong demand during the first quarter. Also, in Europe the bone master hip implant was introduced to the market, which is the first hip device to be offered with hydroxyapatite coating.

Clinical trials are ongoing in the US for a new generation of bonesparing primary hip stems. The new balance and Taperloc Microplasty hip system will offer the industry's first and most advanced design features for modern hip stem while maintaining the clinically proven Biomet's design philosophy. The design rational for these reduced length component wills be suited to those surgeons offering minimally invasive hip procedures along with surgeons whose design preference is proximally coated primary hip. Surgeon feedback continues to be positive with more than 225 Microplasty stems implanted during the past five quarters. and Europe during the past quarter. Todate, approximately 100 ASI instrument sets have been rolled out and more than 80 surgeons have received ASI training with additional ASI labs scheduled throughout fiscal 2007.

ArComXL, Biomet's highly crosslinked polyethylene, continued to receive excellent market acceptance during the first quarter. ArCom provides a 47% to 64% decrease in volumetric wear rates over standard ArCom in laboratory studies and offers a 30% increase in ultimate tensile strength along with similar wearparticle shape and size with no measurable oxidation exhibited for cell rated agents. Clinical evaluations are underway for Biomet's Regenerex Titanium Construct, and we are scheduled to initiate the launch a Regenerex cup and augment midway through this fiscal year. As a result of Biomet's pioneering efforts, Titanium has become a clinically proven material in the orthopedic market, resulting in optimal biological fixation. We believe the longterm clinical success of Biomet's Titanium implants will translate into strong demand for Regenerex as the material of choice for porous metal constructs.Turning now to extremities, sales increased 13% worldwide during the first quarter and increased 8% in the United States. Extremity products that experienced strong worldwide growth during the first quarter include the Discovery Elbow, Copeland [Humal] Resurfacing Head, Comprehensive Fracture Stem, ExploR Radial Head Replacement and the Maestro Wrist Reconstructive System, as well as the test shoulder system which is available in Europe.